Benitec Biopharma Adds 4%

Benitec Biopharma gained almost 4% in morning trade Monday after it initiated work on two new oncology pipeline programs after executing a research collaboration agreement with Nant Capital LLC.

Under the terms of the agreement, Benitec has taken control of the clinical development of BB-401, a recombinant DNA construct that produces an antisense RNA with specificity against Epidermal Growth Factor Receptor.

Benitec says it has assembled a team of experts to articulate the plans for the rapid progression of BB-401 into the next stages of development, which includes plans to meet with the Food and Drug Administration and other regulatory agencies and targets starting a midstage human clinical study early in 2018.

By Sara Howard